Zhang Huifang, Liu Yang, Shang Xiyu, Cao Yuqing, Li Jiajia, Chen Guangkun, Ji Xinyu, Zhang Lei, Fan Yipin, Ma Yan
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Shaanxi Academy of Traditional Chinese Medicine, Xi'an, China.
Front Pharmacol. 2024 Jul 31;15:1422773. doi: 10.3389/fphar.2024.1422773. eCollection 2024.
Qingfei Paidu Decoction (QFPDD) has played an important role in the prevention and treatment of COVID-19 infection in China. The present study aims to perform an econometric analysis and visualization of the literature on the treatment of COVID-19 with QFPDD in the Chinese databases and English databases.
Six databases including such as Chinese databases CNKI, VIP, CBM, WANFANG as well as English databases PubMed, Web of Science were searched for publications related to the prevention and treatment of COVID-19 with QFPDD. The institutions, authors, keywords of each publication were cisualized using the software of CiteSpace.
A total of 187 literature on the prevention and treatment of novel coronavirus infection with QFPDD were included, of which 145 (77.5%) were in Chinese and 42 (22.5%) were in English. Those publications were written by 926 authors from 383 institutions. There were 78 theoretical studies (41.7%), 63 clinical studies (33.7%), and 46 basic studies (24.6%). The cooperative institutions with the core of "Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences" and "Shanghai University of Chinese Medicine Cross Academy of Science" have been formed, and two core teams with "Wang Yanping" and "Zhang Weidong" have been formed. The keyword analysis showed that the research mainly focuses on pathologic pathogenesis, clinical efficacy, adverse reactions, integrated Chinese and western medicine therapy, network pharmacology research.
QFPDD has attracted worldwide attention, mechanism research and clinical research may become a future development trend. Therefore, in-depth basic research and clinical studies with large samples and multi-center cooperation should be carried out to provide high-level evidence-based evidence for the prevention and treatment of COVID-19 with QFPDD.
清肺排毒汤在中国新型冠状病毒肺炎(COVID-19)感染的防治中发挥了重要作用。本研究旨在对中国数据库和英文数据库中有关清肺排毒汤治疗COVID-19的文献进行计量分析和可视化。
检索了6个数据库,包括中国知网(CNKI)、维普(VIP)、中国生物医学文献数据库(CBM)、万方以及英文数据库PubMed、Web of Science,以查找与清肺排毒汤防治COVID-19相关的出版物。使用CiteSpace软件对每份出版物的机构、作者、关键词进行可视化。
共纳入187篇关于清肺排毒汤防治新型冠状病毒感染的文献,其中中文文献145篇(77.5%),英文文献42篇(22.5%)。这些出版物由来自383个机构的926位作者撰写。有78项理论研究(41.7%)、63项临床研究(33.7%)和46项基础研究(24.6%)。形成了以“中国中医科学院中医临床基础医学研究所”和“上海中医药大学交叉科学研究院”为核心的合作机构,以及以“王燕平”和“张伟东”为核心的两个团队。关键词分析表明,研究主要集中在病理病机、临床疗效、不良反应、中西医结合治疗、网络药理学研究等方面。
清肺排毒汤已引起全球关注,机制研究和临床研究可能成为未来的发展趋势。因此,应开展深入的基础研究和大样本、多中心合作的临床研究,为清肺排毒汤防治COVID-19提供高水平的循证依据。